Market Tracker

08/24 6:11am ET

Novo Nordisk A/S (NYSE:NVO)

47.41
Delayed Data
As of Aug 23
 -0.08 / -0.17%
Today’s Change
45.80
Today|||52-Week Range
59.00
-18.37%
Year-to-Date
Better Buy: AbbVie Inc. vs. Eli Lilly & Co.
Aug 17 / MotleyFool.com - Paid Partner Content
Top 3 Research Reports for August 12, 2016
Aug 12 / Zacks.com - Paid Partner Content
Novo Nordisk A/S Focuses on New Drugs
Aug 16 / MotleyFool.com - Paid Partner Content
Novo Nordisk (NVO) Beats Q2 Earnings, Revenues Up Y/Y
Aug 08 / Zacks.com - Paid Partner Content
3 Beaten-Up Big Pharma Stocks: Are They Bargains?
Aug 14 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close47.49
Today’s open47.65
Day’s range47.32 - 47.75
Volume3,381,352
Average volume (3 months)1,807,500
Market cap$93.1B
Dividend yield0.96%
Data as of 08/23/2016

Growth & Valuation

Earnings growth (last year)+12.05%
Earnings growth (this year)--
Earnings growth (next 5 years)+10.82%
Revenue growth (last year)+1.43%
P/E ratio3.4
Price/Sales9.38
Price/Book17.70

Competitors

 Today’s
change
Today’s
% change
CELGCelgene-0.19-0.17%
LLYEli Lilly and Co+0.28+0.35%
BMYBristol-Myers Squibb+0.60+1.01%
AGNAllergan-0.33-0.13%
Data as of 08/23/2016

Financials

Next reporting dateOctober 28, 2016
EPS forecast (this quarter)$0.57
Annual revenue (last year)$16.0B
Annual profit (last year)$5.2B
Net profit margin32.30%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
President &
Chief Executive Officer
Lars Rebien Sørensen
Chief Financial Officer &
Executive Vice President
Jesper Brandgaard
Corporate headquarters
Bagsværd, Capital Region

Forecasts